Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

China Delays Implementation Of Essential Drugs List; Analysts Say List Has Less Impact Than Earlier Predicted

This article was originally published in PharmAsia News

Executive Summary

SHANGHAI - China's Ministry Of Health announced it will delay implementation of the Essential Drug List in 30 percent of government-controlled clinics until the end of March

You may also be interested in...



Jiangbo Launches Generic Of Astrazeneca's Plendil, Targeting 153 Million Hypertension Patients In China

SHANGHAI - Nasdaq-listed Chinese pharma Jiangbo received approval from China's State FDA to manufacture Felodipine Sustained Release Tablets, a generic version of Plendil (felodipine)

Jiangbo Launches Generic Of Astrazeneca's Plendil, Targeting 153 Million Hypertension Patients In China

SHANGHAI - Nasdaq-listed Chinese pharma Jiangbo received approval from China's State FDA to manufacture Felodipine Sustained Release Tablets, a generic version of Plendil (felodipine)

China's New Guideline For Drug Pricing Favors Innovation And First-to-market Generics

SHANGHAI - The National Development and Reform Commission, China's powerful economic regulatory body, is collecting feedback from industry for a new drug pricing guideline, which details new rules for setting drug prices in China's changing healthcare system

Related Content

Latest News
See All
UsernamePublicRestriction

Register

SC074178

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel